CFA
CRL icon

CWS Financial Advisors’s Charles River Laboratories CRL Stock Holding History

CWS Financial Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-382
Closed -$74.9K – 150
2023
Q3 		$74.9K Buy
+382
New +$78.4K 0.03% 152
2023
Q1 		– Sell
-1,045
Closed -$303K – 149
2022
Q4 		$303K Buy
+1,045
New +$228K 0.13% 106
2021
Q2 		$358K Sell
967
-78
-7% -$26K 0.14% 105
2021
Q1 		$303K Buy
1,045
+9
+0.9% +$2.5K 0.13% 106
2020
Q4 		$259K Buy
1,036
+12
+1% +$2.86K 0.15% 107
2020
Q3 		$232K Buy
+1,024
New +$213K 0.15% 108

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

CWS Financial Advisors's CRL Position: Q4 2023 in Review

CWS Financial Advisors sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 382 shares — an estimated $74.9K sold.

CWS Financial Advisors first reported a position in CRL in Q3 2020 and held it in 6 quarters. The position peaked at $358K in Q2 2021. 634 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

  • CWS Financial Advisors reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
  • CWS Financial Advisors sold 382 Charles River Laboratories shares in Q4 2023, an estimated $74.9K.
  • CWS Financial Advisors first reported a position in Charles River Laboratories in Q3 2020 and held it in 6 quarters.
  • CWS Financial Advisors's Charles River Laboratories position peaked at $358K in Q2 2021.
  • 634 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on CWS Financial Advisors's 13F filing for Q4 2023, filed 8 Feb 2024.